Heparin is a valuable anticoagulant, but it can induce severe immunologic reactions at any dose. The authors present a comprehensive review of the pathophysiology, etiology, diagnosis, laboratory findings, and therapeutic management of thrombocytopenia that can result from this antithrombotic agent.
You are here
P&T® Journal contents for November 2008
Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose To Free-Combination Antihypertensive Therapy
In an evaluation of patients who were switched from fixed-dose combination (FDC) to free-combination (FC) therapy for elevated blood pressure, the authors found that patients continuing with the FDC regimen had better persistence and compliance compared with patients who were switched to FC therapy. Greater compliance with the FDC regimen was also associated with lower health care costs and with less use of health care–related resources.
Some of the topics covered at this oncology meeting included cetuximab (Erbitux) for colorectal cancer, pazopanib and antibody CP-751871 for non–small-cell lung cancer; Everolimus (Certican) for pancreatic tumors; lapatinib (Tykerb) for squamous cell carcinoma; and Elesclomol for melanoma. Denosumab and odanacatib, presented at the bone and mineral research meeting, were found to increase bone density and build new bone.
Romiplostim (Nplate) for thrombocytopenia; palonosetron capsules (Aloxi) for chemotherapy-induced nausea and vomiting; and iobenguane iodine-123 injection (AdreView), used for diagnosing primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other tests, are discussed.